Role of survivin as prognostic and clinicopathological marker in gastric cancer: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 9, 2013, Pages 5501-5511

  Krieg, Andreas ^a   Baseras, Billur ^a   Tomczak, Monika ^a   Verde, Pablo Emilio ^a   Stoecklein, Nikolas Hendrik ^a   Knoefel, Wolfram Trudo ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

BIRC5; Clinicopathological variables; Gastric cancer; Prognosis; Survivin

Indexed keywords

SURVIVIN;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SYSTEMATIC REVIEW;

GENETIC MARKERS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; ODDS RATIO; PROGNOSIS; PUBMED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84883293141     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2650-z     Document Type: Article

References (50)

1. Organization WH (2012) Cancer (Fact sheet No. 297). WHO website. Accessed 15 Jan 2013
2. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137-2150
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36-46
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991-4997
5. Wagner AD, Moehler M (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 21(4):381-385
6. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85(9):1894-1902
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697
8. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA FA Jr (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29(22):3030-3036
9. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77(5):858-863
10. Smyth EC, Cunningham D (2012) Targeted therapy for gastric cancer. Curr Treat Options Oncol 13(3):377-389
11. de Almagro MC, Vucic D (2012) The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 34(3):200-211
12. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917-921
13. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL (2000) Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151(7):1575-1582
14. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279(33):34087-34090
15. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC (2010) IAP regulation of metastasis. Cancer Cell 17(1):53-64
16. Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58(9):1808-1812
17. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58(22):5071-5074
18. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD (2002) Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86(5):737-743
19. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD (2002) Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100(1):30-36
20. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4):705-719
21. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815-2834
22. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820-826
23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558
24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188
25. Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P, Sung JJ (2002) Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 87(1):91-97
26. Tsuburaya A, Noguchi Y, Yoshikawa T, Saito A, Doi C, Okamoto T, Fukuzawa K (2002) An anti-apoptosis gene, survivin and telomerase expression in gastric cancer. Hepatogastroenterology 49(46):1150-1152
27. Wakana Y, Kasuya K, Katayanagi S, Tsuchida A, Aoki T, Koyanagi Y, Ishii H, Ebihara Y (2002) Effect of survivin on cell proliferation and apoptosis in gastric cancer. Oncol Rep 9(6):1213-1218
28. Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H, Sunagawa M (2003) Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 6(4):217-224
29. Zhu XD, Lin GJ, Qian LP, Chen ZQ (2003) Expression of survivin in human gastric carcinoma and gastric carcinoma model of rats. World J Gastroenterol 9(7):1435-1438
30. Meng H, Lu C, Mabuchi H, Tanigawa N (2004) Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 216(2):147-155
31. Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, Torigoe T, Sato N, Watanabe N (2004) Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 95(1):44-51
32. Wang ZN, Xu HM, Jiang L, Zhou X, Lu C, Zhang X (2004) Expression of survivin in primary and metastatic gastric cancer cells obtained by laser capture microdissection. World J Gastroenterol 10(21):3094-3098
33. Chang JL, Chen TH, Wang CF, Chiang YH, Huang YL, Wong FH, Chou CK, Chen CM (2006) Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein and its nuclear accumulation is linked to poor prognosis for human gastric cancer. Exp Cell Res 312(7):962-973
34. Deng H, Wu RL, Zhou HY, Huang X, Chen Y, Liu LJ (2006) Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol 12(7):1013-1017
35. Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH, Kim HS, Choi SK, Rew JS, Park CS, Kim SJ (2006) Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol 18(9):957-963
36. Da CL, Xin Y, Zhao J, Luo XD (2009) Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 15(32):4055-4061
37. Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K, Takenoshita S (2009) CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 22(4):745-755
38. Song KY, Jung CK, Park WS, Park CH (2009) Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol 39(5):290-296
39. Li Y, Tan BB, Fan LQ, Zhao Q, Liu Y, Wang D (2010) Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis. Hepatogastroenterology 57(104):1435-1441
40. Kim MA, Lee HE, Lee HS, Yang HK, Kim WH (2011) Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch 459(5):503-510
41. Bury J, Szumilo J, Dabrowski A, Ciechanski A, Sliwinska J, Wallner G (2012) Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma. Pol Przegl Chir 84(7):341-347
42. Meng JR, Tang HZ, Zhou KZ, Shen WH, Guo HY (2012) TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med
43. Zheng WE, Chen H, Yuan SF, Wu LL, Zhang W, Sun HY, Chen WJ (2012) Overexpression of betaIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J Buon 17(2):284-290
44. Piccirillo JF (1995) Purposes, problems, and proposals for progress in cancer staging. Arch Otolaryngol Head Neck Surg 121(2):145-149
45. Nomura M, Shitara K, Kodaira T, Hatooka S, Mizota A, Kondoh C, Yokota T, Takahari D, Ura T, Muro K (2012) Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 82(2):946-952
46. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G (1997) Language bias in randomised controlled trials published in English and German. Lancet 350(9074):326-329
47. Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W, Chen H, Su C (2012) Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis. PLoS One 7(9):e44764
48. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R (2012) Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 7(3):e34100
49. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC (2003) Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63(22):7724-7732
50. Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N (2005) A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11(4):1474-1482